Powered by: Motilal Oswal
2026-04-22 03:33:42 pm | Source: Accord Fintech
iSERA Lifesciences touches roof on getting nod to acquire 100% stake in iSERA Biological
iSERA Lifesciences touches roof on getting nod to acquire 100% stake in iSERA Biological

iSERA Lifesciences is currently trading at upper limit of Rs. 72.71, up by 1.42 points or 1.99% from its previous closing of Rs. 71.29 on the BSE.

The scrip opened at Rs. 72.71 and has touched a high and low of Rs. 72.71 and Rs. 72.71 respectively. So far 25 shares were traded on the counter.

The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 72.71 on 22-Apr-2026 and a 52 week low of Rs. 1.50 on 03-Jul-2025.

Last one week high and low of the scrip stood at Rs. 72.71 and Rs. 67.19 respectively. The current market cap of the company is Rs. 61.14 crore.

The promoters holding in the company stood at 58.63%, while Non-Institutions held 41.37% stake in the company.

iSERA Lifesciences has received approval from Board of Directors for acquisition of equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological, an unlisted public company, comprising up to 1,61,82,800 equity shares of face value Rs 10 each, from the existing shareholders of iSERA Biological, for a total consideration of Rs 78,00,10,960. Upon completion of the said acquisition, iSERA Biological shall become a wholly owned subsidiary of iSERA Lifesciences.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here